Financial Data and Key Metrics Changes - The company's revenue for Q4 2025 surged to CNY 105.2 million, representing a 13% year-over-year and 16% sequential growth [5] - Gross profit grew by 23% year-over-year and 9% quarter-over-quarter, marking the highest gross profit in the past 16 quarters [6][17] - Net operating cash inflow reached CNY 35.1 million, the highest since Q4 2020 [6][21] - The company achieved its first-ever full-year GAAP net profit in 2025 [5][23] Business Line Data and Key Metrics Changes - Developer subscription services revenue grew by 13% year-over-year and 8% quarter-over-quarter, reaching CNY 61.9 million [9][24] - EngageLab's ARR reached $10 million, representing a 186% year-over-year growth [10][24] - Value-Added Services revenue increased by 101% quarter-over-quarter but decreased by 13% year-over-year [9] - Financial risk management revenue grew by 43% year-over-year and 12% quarter-over-quarter [15] Market Data and Key Metrics Changes - EngageLab products are now sold in over 70 countries, with a 142% year-over-year increase in customer numbers [10][11] - The company expanded its footprint into 18 new countries in Q4 alone [11] - The total deferred revenue reached CNY 178.7 million, a historical high [19][20] Company Strategy and Development Direction - The company plans to continue its expansion path with a focus on enhancing products and services while maintaining strong financial management [7] - The theme for 2026 is "growth acceleration," indicating a commitment to capitalize on global opportunities [7] - The company has made significant investments in developing EngageLab specifically for overseas markets [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth prospects for 2026, projecting full-year revenue guidance between CNY 450 million and CNY 480 million, representing a 20%-28% year-over-year growth [25] - The management highlighted the importance of the EngageLab product as a key growth driver for the next three years [36] - The company is confident in its ability to maintain profitability and positive cash flow moving forward [36] Other Important Information - The company repurchased 73,000 ADS in Q4 2025, totaling 400,000 ADS since the start of the repurchase program [25] Q&A Session Summary Question: What are the top three things the company has done well to achieve strong financials? - Management highlighted the courage to venture overseas, the monumental shift in product offerings for global markets, and the commitment to excel throughout the organization as key factors [27][28][30] Question: How should investors view the run-rate financials for Q1 2026 and beyond? - Management indicated that the company has proven its ability to achieve full-year net profit, expects stable growth in domestic business, and anticipates EngageLab to drive significant growth momentum [36]

Financial Data and Key Metrics Changes - The company's revenue for Q4 2025 surged to CNY 105.2 million, representing a 13% year-over-year and 16% sequential growth [5] - Gross profit grew by 23% year-over-year and 9% quarter-over-quarter, marking the highest gross profit in the past 16 quarters [6][18] - The company achieved its first-ever full-year GAAP net profit in 2025, concluding the year on a high note [18][24] - Net operating cash inflow reached CNY 35.1 million, the highest since Q4 2020 [6][22] Business Line Data and Key Metrics Changes - Developer subscription services revenue grew by 13% year-over-year and 8% quarter-over-quarter, reaching CNY 61.9 million [10][24] - EngageLab's ARR reached $10 million as of December 2025, representing a remarkable 186% year-over-year growth [11][24] - Value-added services revenue increased by 101% quarter-over-quarter but decreased by 13% year-over-year [10] Market Data and Key Metrics Changes - The number of EngageLab customers increased by 142% year-over-year, reaching 1,641 [11] - EngageLab products are now sold in over 70 countries, with expansion into 18 new countries in Q4 alone [12] Company Strategy and Development Direction - The company plans to continue its expansion path into 2026, focusing on enhancing products and services while maintaining strong financial management [8][25] - The theme for 2026 is "growth acceleration," building on the successes of 2025 [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing a solid foundation for growth and readiness to seize global opportunities [7][8] - The company anticipates 2026 full-year revenue guidance in the range of CNY 450 million to CNY 480 million, reflecting a 20%-28% year-over-year growth [25] Other Important Information - The company repurchased 73,000 ADS in Q4 2025, totaling 400,000 ADS since the start of the repurchase program [25] Q&A Session Summary Question: What are the top three things the company has done well to achieve these financial results? - Management highlighted the courage to venture overseas, the monumental shift in product offerings for global markets, and the commitment to excel throughout the organization as key factors for success [27][28][30] Question: How should investors view the run-rate financials for Q1 2026 and beyond? - Management indicated that the company has proven its ability to achieve full-year net profit with positive cash inflow, stable domestic business growth, and that EngageLab will drive significant growth momentum in the coming years [35][36]

Aclarion Conference Call Summary Company Overview - Aclarion (NasdaqCM:ACON) is a healthcare technology company focused on non-invasive diagnostic solutions for chronic low back pain, specifically through its product, NOSI scan [1][2] Industry Context - Chronic low back pain affects approximately 266 million people globally, contributing significantly to opioid addiction and leading to costly surgical interventions [3][4] - The lumbar fusion market in the United States is valued at $10 billion, with a broader market encompassing various invasive procedures estimated at $40 billion [5][6] Key Points and Arguments - **Financial Position**: Aclarion has zero debt, no preferred shares, and is fully compliant with Nasdaq requirements. The company has a cash burn rate of $2 million and a runway through 2027 [1][34] - **Scan Volume Growth**: The company has experienced consistent double-digit growth in scan volume over three consecutive quarters, supported by expanding physician referrals [1][2] - **Clinical Evidence**: Aclarion has funded a national randomized control trial (CLARITY trial) to validate the effectiveness of NOSI scan, with initial results from a previous trial showing a 97% positive outcome when surgery matched NOSI scan recommendations [2][19][20] - **Market Opportunity**: The company targets the largest single expenditure in healthcare, with a significant revenue opportunity in the lumbar fusion market alone estimated at $603 million [5][6][35] - **Innovative Technology**: NOSI scan utilizes MR spectroscopy to identify biomarkers in discs that cause pain, offering a non-invasive alternative to traditional, painful diagnostic methods [8][10][16] - **Regulatory and Reimbursement Landscape**: Aclarion has secured reimbursement from three of the top four payers in London, which is expected to drive adoption and growth in the U.S. market as well [26][27] Additional Important Insights - **Intellectual Property**: Aclarion holds 24 issued US patents and 17 international patents related to its technology, enhancing its competitive edge [14] - **Management Team**: The management team includes experienced professionals from the healthcare and technology sectors, which is expected to drive the company's strategic initiatives [32][33] - **Future Catalysts**: Key catalysts for growth include the results from the CLARITY trial, increased physician adoption, and ongoing marketing initiatives in both the U.S. and London [36] Conclusion - Aclarion is positioned to capitalize on a significant market opportunity in chronic low back pain diagnostics through its innovative NOSI scan technology, backed by strong clinical evidence and a solid financial foundation [35][36]